rewrite this title and make it good for SEOFortress Biotech’s Cyprium enters agreement to sell PRV for $205M

Fortress Biotech (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205M upon the closing of the transaction. In December 2023, Sentynl Therapeutics assumed full responsibility for the development and commercialization of ZYCUBO from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration on January 12, 2026. Pursuant to the transaction with Sentynl, the PRV was immediately transferred to Cyprium. Cyprium remains eligible to receive tiered royalties on net sales of ZYCUBO and up to $129M in aggregate development and sales milestones from Sentynl. Cyprium is also obligated to pay 20% of the proceeds from a PRV sale to the Eunice Kennedy Shriver National Institute of Child Health and Human Development, an institute of the National Institutes of Health. The transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on FBIO:

Disclaimer & DisclosureReport an Issue